Released On: March 4, 2022
Expires On: March 4, 2023
This activity is jointly provided by The Consortium of Multiple Sclerosis Centers (CMSC) and Catamount Medical Education.
This activity is supported by an independent educational grant from
Bayer HealthCare Pharmaceuticals Inc.
Credit Available
- Physicians — maximum of 0.25 AMA PRA Category 1 Credit(s)™
- Nurses — 0.25 contact hours of nursing continuing professional development credit (NCPD) (0.25 in the area of pharmacology)
- Pharmacists — 0.25 contact hours (0.025 CEUs) of continuing pharmacy education credit.
All other health-care professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of neurologists, advanced practice clinicians, nurses, pharmacists, and other members of the healthcare team caring for patients with MS.
Program Overview
Four case-based podcasts that provide expert, evidence-based insights on the development of personalized treatment plans for MS patients who are or who plan to become pregnant.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify factors that may influence the decision to start or delay disease-modifying therapy after MS diagnosis in a patient who is planning to become or is currently pregnant
- Employ evidence-based considerations and strategies for discontinuing and/or switching DMT in a patient who wishes to become pregnant
- Analyze data on the safety of available DMTs during pregnancy
- Integrate evidence and considerations related to the use of DMTs in the post-partum period and during breastfeeding
Faculty
Riley Bove, MD, MSc
Associate Professor
UCSF Weill Institute for Neurosciences
Mitzi Joi Williams, MD
Founder and CEO
Joi Life Wellness Group, LLC
Contact Information
For questions about this activity, please contact Catamount Medical Education at [email protected].
